Diamyd Medical announced the Food and Drug Administration (FDA) granted its type 1 diabetes drug candidate Diamyd® Orphan Drug Designation.
Orphan drugs qualify for several incentives including a seven-year period of market exclusivity in the US...
Category: Research
The Juvenile Diabetes Research Foundation (JDRF) said that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes...
Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that following positive phase 2 study results in a new obesity treatment, they will advance towards phase 3 development of a combination treatment for obesity which includes pramlintide (an analog of the natural hormone amylin) and metreleptin (an analog of the natural hormone leptin)...
A new study shows vinegar reduces post-meal hyperglycemia in type 1 diabetics. While previous studies have shown that vinegar improves insulin sensitivity in healthy or insulin-resistant subjects, information on the effect of vinegar in type 1 diabetes has been absent....
Diabetic retinopathy is a common side effect of diabetes and the leading cause of blindness in young adults in the United States. Scientists have long known that high blood sugar levels damage blood vessels in the eye, but they didn't know why or how this happens. Now a Michigan State University scientist has...
Diamyd Medical AB, a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, announced it plans to file the Diamyd® diabetes vaccine for market approval in 2011...
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris.
Calibra Medical Inc., formerly known as Seattle Medical Technologies Inc., announced today that the U.S. Food and Drug Administration has given Finesse, the company’s insulin patch-pen, 510(k) clearance.
Only 2” long, 1” wide and ¼” thick, Finesse is able to hold and deliver prescribed amounts of insulin over multiple days while...
The Juvenile Diabetes Research Foundation announced today in a press release that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes...
Diamyd Medical, a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, reports today that the US FDA has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America...